

James

a 4-year-old male diagnosed with congenital athymia

Presentation and diagnosis

- T cell receptor excision circle (TREC) newborn screening detected a deficiency of naive T cells, which may indicate either severe combined immunodeficiency (SCID) or congenital athymia¹
- Underwent complete blood count differential and lymphocyte phenotyping by flow cytometry. Fewer than 50 naive T cells/mm³ were detected in the peripheral blood. The patient presented with a T[·]B⁺NK⁺ phenotype, indicating a need for further testing¹
- Additional **panel-based genetic testing** ruled out SCID¹
- Chromosomal microarray identified 22q11.2 deletion, confirming a congenital athymia diagnosis associated with complete DiGeorge syndrome¹

This is a hypothetical patient case study and is not indicative of treatment outcomes.

The steps to confirming a diagnosis presented here are not exhaustive and may differ on a case-by-case basis.

Additional supportive care may be needed to manage a patient's associated conditions. These may include complete DiGeorge syndrome (22q11.2 deletion syndrome), CHARGE* syndrome, *FOXN1* deficiency, and diabetic embryopathy.¹

Supportive care plan

- Infection control measures were initiated in the hospital immediately following the positive TREC screening results and suspicion of congenital athymia¹
 - Isolation: The patient was placed in a room with laminar air flow (LAF). Visitors were required to properly sterilize and wear personal protective equipment (PPE) before entering¹
 - **Supportive therapies:** Started on prophylaxis for *Pneumocystis jirovecii*; immunoglobulin (IgG) replacement therapy; and antibiotic, antimicrobial, and antifungal prophylaxis^{1,2}
 - Received no live or inactive vaccines³
 - Mother was instructed to stop breastfeeding to decrease risk of cytomegalovirus (CMV) transmission¹
- After confirmation of congenital athymia and the patient was deemed appropriate for treatment, the patient was referred to a qualified treatment center to receive RETHYMIC⁴
- **Discharged from the hospital** and brought home until treatment with RETHYMIC became available
- It was recommended that this family follow strict isolation measures, including restricting visitors and frequent handwashing³



Indication

RETHYMIC[®] is indicated for immune reconstitution in pediatric patients with congenital athymia. <u>Limitations of Use:</u> RETHYMIC is not indicated for the treatment of patients with severe combined immunodeficiency (SCID).

Important Safety Information

Infection Control and Immunoprophylaxis: Immune reconstitution sufficient to protect from infection is unlikely to develop prior to 6-12 months after treatment with RETHYMIC. Follow infection control measures until the development of thymic function is established as measured by flow cytometry. Closely monitor patients for signs of infection. If fever develops, assess the patient via lab results and treat as clinically indicated. Patients should be maintained on immunoglobulin replacement therapy (IgG) and *Pneumocystis jirovecii* pneumonia prophylaxis until specified criteria are met. IgG trough level should be checked 2 months after stopping IgG to determine whether the patient may remain off IgG.

Please see additional Important Safety Information throughout, and full <u>Prescribing Information</u>.

*Coloboma, heart defects, atresia of the nasal choanae, retardation of growth and development, genitourinary anomalies, and ear anomalies.



James' congenital athymia treatment journey

This is a hypothetical patient case study and is not indicative of treatment outcomes or timing. Exact timelines may vary from patient to patient. Please see full <u>Prescribing Information</u> for guidance on testing and monitoring parameters.

Birth	1 Week	2 Weeks		2 Years	The journey continues 🕨
	Positive TREC reening results	James' congenital a diagnosis was con		James received treatment with RETHYMIC at a qualified treatment center⁴	
At suspicion of congenital athymia ¹ : • Infection control measures were initia		 After diagnosis was confirmed⁴: Referred for treatment with RETHYMIC 	 Prior to receiving treatment with RETHYMIC⁴: Tested for Epstein-Barr virus (EVB), CMV infection, and renal impairment to assess the risks and benefits of receiving treatment with RETHYMIC After returning to the care of his referring Monitored closely for signs of infection, included by blood and other cultures and treating with clinically indicated 		ection, including fever. ols included assessing the patient
			 Thyroid function studies were performed to monitor for autoimmune disorders 	 Naive T-cell counts were monitored using flow cytometry every 3 months until naive T cells were greater than 10% of total T cells 	
			 Screens for anti-HLA antibodies were negative HLA matching was not required as the patient had not received a prior hematopoietic cell transplantation (HCT) or solid organ transplant 	 Monitored for autologous graft versus host disease (GVHD) and autoimmune disorders. Tests for monitoring autoimmune disorders included or measured: Complete blood count with differential (weekly in the first 2 months after treatment) 	
					ine levels, and urinalysis (monthly

Important Safety Information (cont'd)

Graft versus Host Disease (GVHD): RETHYMIC may cause or exacerbate pre-existing GVHD, for which patients should be closely monitored and treated. Risk factors include atypical complete DiGeorge anomaly phenotype, prior hematopoietic cell transplantation (HCT), and maternal engraftment. Patients with specified elevated baseline T cell proliferative response to PHA should receive immunosuppressants to decrease this risk. GVHD may manifest as fever, rash, lymphadenopathy, elevated bilirubin and liver enzymes, enteritis, and/or diarrhea.


Autoimmune Disorders: Autoimmune-related adverse events occurred in patients treated with RETHYMIC. These events included thrombocytopenia, neutropenia, proteinuria, hemolytic anemia, alopecia, hypothyroidism, autoimmune hepatitis, autoimmune arthritis, transverse myelitis, albinism, hyperthyroidism, and ovarian failure. Monitor complete blood counts with differential, liver enzymes, serum creatinine, urinalysis, and thyroid function.

Please see additional Important Safety Information throughout, and full Prescribing Information.



Continuing to monitor James after treatment with RETHYMIC

This is a hypothetical patient case study and is not indicative of treatment outcomes or timing. Exact timelines may vary from patient to patient. Please see full <u>Prescribing Information</u> for guidance on testing and monitoring parameters.



Important Safety Information (cont'd)

Renal Impairment: Pre-existing renal impairment is a risk factor for death.

Cytomegalovirus Infection (CMV): In the clinical studies, 4 out of 4 patients with pre-existing CMV infection died.

Malignancy: Due to underlying immune deficiency, patients who receive RETHYMIC may be at risk of developing post-treatment lymphoproliferative disorder. Patients should be tested for Epstein-Barr virus and CMV prior to

and 3 months after treatment or after any suspected exposure.

Transmission of Serious Infections and Transmissible Infectious Diseases: Transmission of infectious disease may occur because RETHYMIC is derived from human tissue, and product manufacturing includes porcine- and bovine-derived reagents.

Please see additional Important Safety Information throughout, and full Prescribing Information.



Relaxing James' infection prevention measures and administering vaccines

This is a hypothetical patient case study and is not indicative of treatment outcomes or timing. Exact timelines may vary from patient to patient. Please see full <u>Prescribing Information</u> for guidance on testing and monitoring parameters.

3 Years		3 Years, 3 Months James received his first inactivated vaccine ⁴			4 Years James' current age
Continued testing to determi discontinue supportive care treat					
 12 months after treatment^{3,4}: At least 10% of CD3⁺ T cells were naive in phenotype Patient met all requirements and began discontinuing immunosuppression Naive T-cell counts were monitored using flow cytometry Thyroid function studies were performed From this point, monitoring of naive T-cell counts and tests for monitoring autoimmune disorders were performed every 12 months 	 After discontinuing immunosuppression⁴: Phytohemagglutinin (PHA) response was within normal limits Patient met all requirements and began discontinuing IgG replacement therapy Once the CD4⁺ cell count was determined to be >200 cells/mm³ and the patient met all requirements, the patient began discontinuing prophylaxis for <i>Pneumocystis jirovecii</i> 	 2 months after discontinuing IgG replacement therapy⁴: IgG trough levels were checked 2 months after discontinuation Levels were determined to be in the normal range and the patient remained off IgG replacement therapy 	 15 months after treatment*: Total CD4* T-cell count was >200 cells/mm³ CD4* T cells outnumbered CD8* T cells No more than 2 inactivated vaccines were received per month Live virus vaccines should not be for inactivated vaccines have beer received vaccinations with inactive See all of the requirements for inactivation.4 	n met and the patient has	Learn more about congenital athymia and treatment with RETHYMIC. Visit RETHYMIC.com/hcp

Important Safety Information (cont'd)

Vaccine Administration: Immunizations should not be given in patients treated with RETHYMIC until immunefunction criteria have been met. Live virus vaccines should not be given until patients have met the criteria for and received inactivated vaccines.

Anti-HLA Antibodies: All patients should be screened for anti-HLA antibodies prior to receiving RETHYMIC.

Patients testing positive should receive RETHYMIC from a donor who does not express those HLA alleles.

HLA Typing: HLA matching is required in patients who have received a prior HCT or a solid organ transplant. Patients who have received a HCT are at increased risk of developing GVHD after RETHYMIC if the HCT donor does not fully match with RETHYMIC.

Please see additional Important Safety Information throughout, and full Prescribing Information.



Indication

RETHYMIC[®] is indicated for immune reconstitution in pediatric patients with congenital athymia.

<u>Limitations of Use</u>: RETHYMIC is not indicated for the treatment of patients with severe combined immunodeficiency (SCID).

Important Safety Information

Infection Control and Immunoprophylaxis: Immune reconstitution sufficient to protect from infection is unlikely to develop prior to 6-12 months after treatment with RETHYMIC. Follow infection control measures until the development of thymic function is established as measured by flow cytometry. Closely monitor patients for signs of infection. If fever develops, assess the patient via lab results and treat as clinically indicated. Patients should be maintained on immunoglobulin replacement therapy (IgG) and *Pneumocystis jirovecii* pneumonia prophylaxis until specified criteria are met. IgG trough level should be checked 2 months after stopping IgG to determine whether the patient may remain off IgG.

Graft versus Host Disease (GVHD): RETHYMIC may cause or exacerbate pre-existing GVHD, for which patients should be closely monitored and treated. Risk factors include atypical complete DiGeorge anomaly phenotype, prior hematopoietic cell transplantation (HCT), and maternal engraftment. Patients with specified elevated baseline T cell proliferative response to PHA should receive immunosuppressants to decrease this risk. GVHD may manifest as fever, rash, lymphadenopathy, elevated bilirubin and liver enzymes, enteritis, and/or diarrhea.

Autoimmune Disorders: Autoimmune-related adverse events occurred in patients treated with RETHYMIC. These events included thrombocytopenia, neutropenia, proteinuria, hemolytic anemia, alopecia, hypothyroidism, autoimmune hepatitis, autoimmune arthritis, transverse myelitis, albinism, hyperthyroidism, and ovarian failure. Monitor complete blood counts with differential, liver enzymes, serum creatinine, urinalysis, and thyroid function.

Renal Impairment: Pre-existing renal impairment is a risk factor for death.

Cytomegalovirus Infection (CMV): In the clinical studies, 4 out of 4 patients with pre-existing CMV infection died.

Malignancy: Due to underlying immune deficiency, patients who receive RETHYMIC may be at risk of developing post-treatment lymphoproliferative disorder. Patients should be tested for Epstein-Barr virus and CMV prior to and 3 months after treatment or after any suspected exposure.

Transmission of Serious Infections and Transmissible Infectious Diseases: Transmission of infectious disease may occur because RETHYMIC is derived from human tissue, and product manufacturing includes porcine- and bovine-derived reagents.

Vaccine Administration: Immunizations should not be given in patients treated with RETHYMIC until immune-function criteria have been met. Live virus vaccines should not be given until patients have met the criteria for and received inactivated vaccines.

Anti-HLA Antibodies: All patients should be screened for anti-HLA antibodies prior to receiving RETHYMIC. Patients testing positive should receive RETHYMIC from a donor who does not express those HLA alleles.

HLA Typing: HLA matching is required in patients who have received a prior HCT or a solid organ transplant. Patients who have received a HCT are at increased risk of developing GVHD after RETHYMIC if the HCT donor does not fully match with RETHYMIC.

Deaths: Of the 105 patients in clinical studies, 29 patients died, including 23 deaths in the first year (<365 days) after implantation.

Adverse Reactions: The most common (>10%) adverse events included hypertension, cytokine release syndrome, rash, hypomagnesemia, renal impairment/failure, thrombocytopenia, and GVHD.

References: 1. Collins C, Sharpe E, Silber A, Kulke S, Hsieh EWY. Congenital athymia: genetic etiologies, clinical manifestations, diagnosis, and treatment. *J Clin Immunol.* 2021;41(5):881-895. doi:10.1007/s10875-021-01059-7 **2.** Markert ML. Defects in thymic development. In: Sullivan KE, Stiehm ER, eds. *Stiehm's Immune Deficiencies: Inborn Errors of Immunity.* 2nd ed. Elsevier; 2020:357-379. **3.** Gupton SE, McCarthy EA, Markert ML. Care of children with DiGeorge before and after cultured thymus tissue implantation. *J Clin Immunol.* 2021;41(5):896-905. doi:10.1007/s10875-021-01044-0 **4.** RETHYMIC [package insert]. Marlborough, MA: Sumitomo Pharma America, Inc; 2023. **5.** Markert ML, McCarthy EA, Gupton SE, Lim AP. Cultured thymus tissue transplantation. In: Sullivan KE, Stiehm ER, eds. *Stiehm's Immune Deficiencies: Inborn Errors of Immunity.* 2nd ed. Elsevier; 2020:1229-1239.

Please see full <u>Prescribing Information</u>.

ENZYVANT CONNECT

Education and financial assistance are available through our patient support program, Enzyvant CONNECT®

Enzyvant CONNECT provides patients and their caregivers with personalized support as they navigate the congenital athymia journey.

Enzyvant CONNECT is available to patients with any type of insurance—including commercial plans, Medicare, or Medicaid—as well as patients who are underinsured or have no insurance coverage.

Call 844-ENZCNCT (844-369-2628) to get connected to personalized support. We're available Monday–Friday, 8:00 AM to 8:00 PM ET.

Enroll your patients today

Sumitomo Pharma America, Inc. and Enzyvant CONNECT are not responsible for treatment decisions or timing for treatment.

Sumitomo Pharma

• is a trademark of Sumitomo Pharma Co., Ltd., used under license. SUMITOMO PHARMA is a trademark of Sumitomo Pharma Co., Ltd., used under license. SUMITOMO is a registered trademark of Sumitomo Chemical Co., Ltd., used under license. Sumitomo Pharma America, Inc. is a U.S. subsidiary of Sumitomo Pharma Co., Ltd. RETHYMIC[®], ENZYVANT CONNECT[®], and their logos are registered trademarks of Sumitomo Pharma Switzerland GmbH. © 2024 Sumitomo Pharma Switzerland GmbH. All rights reserved. US-2300165 04/2024





Dedicated care team

- The Support Liaison will help you understand your child's diagnosis
- The Access Specialist can help you navigate insurance benefits and financial assistance

Access to exclusive resources

- Document organizer
- *Sadie's Search*, a storybook written specifically with your child in mind
- Interactive T-cell progress tracker
- Activity book
- And more!



Co-pay program

- The Enzyvant CONNECT[®] Commercial Co-Pay Program can help caregivers of eligible commercially insured patients in the US and US territories
- You may receive co-pay assistance for medicationrelated out-of-pocket costs for RETHYMIC

